CN104470534A - 用于治疗退变性病症的ledgf肽及其制剂 - Google Patents

用于治疗退变性病症的ledgf肽及其制剂 Download PDF

Info

Publication number
CN104470534A
CN104470534A CN201380038504.6A CN201380038504A CN104470534A CN 104470534 A CN104470534 A CN 104470534A CN 201380038504 A CN201380038504 A CN 201380038504A CN 104470534 A CN104470534 A CN 104470534A
Authority
CN
China
Prior art keywords
ledgf
composition
disease
peptide
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380038504.6A
Other languages
English (en)
Chinese (zh)
Inventor
乌达伊·B·康佩拉
林库·拜德
阿伦·K·乌帕德亚伊
萨拉·扬德拉普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Boulder
Original Assignee
University of Colorado Boulder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/065620 external-priority patent/WO2013074988A1/en
Application filed by University of Colorado Boulder filed Critical University of Colorado Boulder
Priority to CN201811628163.9A priority Critical patent/CN110054677A/zh
Publication of CN104470534A publication Critical patent/CN104470534A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
CN201380038504.6A 2012-05-21 2013-05-21 用于治疗退变性病症的ledgf肽及其制剂 Pending CN104470534A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811628163.9A CN110054677A (zh) 2012-05-21 2013-05-21 用于治疗退变性病症的ledgf肽及其制剂

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261649847P 2012-05-21 2012-05-21
US61/649,847 2012-05-21
USPCT/US2012/065620 2012-11-16
PCT/US2012/065620 WO2013074988A1 (en) 2011-11-17 2012-11-16 Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
PCT/US2013/042074 WO2013177198A1 (en) 2012-05-21 2013-05-21 Ledgf peptides and formulations thereof for treatment of degenerative disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811628163.9A Division CN110054677A (zh) 2012-05-21 2013-05-21 用于治疗退变性病症的ledgf肽及其制剂

Publications (1)

Publication Number Publication Date
CN104470534A true CN104470534A (zh) 2015-03-25

Family

ID=49624295

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811628163.9A Pending CN110054677A (zh) 2012-05-21 2013-05-21 用于治疗退变性病症的ledgf肽及其制剂
CN201380038504.6A Pending CN104470534A (zh) 2012-05-21 2013-05-21 用于治疗退变性病症的ledgf肽及其制剂

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201811628163.9A Pending CN110054677A (zh) 2012-05-21 2013-05-21 用于治疗退变性病症的ledgf肽及其制剂

Country Status (12)

Country Link
US (2) US9526760B2 (enExample)
EP (1) EP2852399B1 (enExample)
JP (2) JP6632376B2 (enExample)
CN (2) CN110054677A (enExample)
AU (1) AU2013266468B2 (enExample)
BR (1) BR112014028951A8 (enExample)
CA (1) CA2873771A1 (enExample)
DK (1) DK2852399T3 (enExample)
ES (1) ES2791251T3 (enExample)
IN (1) IN2014MN02461A (enExample)
RU (1) RU2617964C2 (enExample)
WO (1) WO2013177198A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348544A (zh) * 2015-07-13 2018-07-31 首尔大学校产学协力团 用于抑制血管生成的含有纳米颗粒-玻璃体基蛋白质复合物作为活性成分的组合物及其用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526760B2 (en) * 2012-05-21 2016-12-27 The Regents Of The University Of Colorado, A Body Corporate LEDGF peptides and formulations thereof for treatment of degenerative disorders
US20180207293A1 (en) * 2017-01-25 2018-07-26 2C Tech Corp. Nanoparticles for sustained ophthalmic drug delivery and methods of use
US11793758B2 (en) 2018-06-22 2023-10-24 Bioralix B.V. Formulations of biological polymers for oral administration

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120028889A1 (en) * 2002-09-26 2012-02-02 K.U. Leuven Research & Development Integrase cofactor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221787A (en) 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4469689A (en) 1983-03-30 1984-09-04 The Upjohn Company Sulfonate containing ester prodrugs of corticosteroids
US6750052B1 (en) 1997-07-23 2004-06-15 The Brigham And Women's Hospital, Inc. Lens epithelial cell derived growth factor
US7708915B2 (en) 2004-05-06 2010-05-04 Castor Trevor P Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
WO2004017904A2 (en) 2002-08-23 2004-03-04 The Mclean Hospital Corporation Corticosteroid conjugates and uses thereof
US20040253606A1 (en) * 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
US20060166879A1 (en) 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
US20050181375A1 (en) * 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
WO2005118869A2 (en) * 2004-05-28 2005-12-15 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
JP5247468B2 (ja) 2005-12-30 2013-07-24 ニューロテック ユーエスエー， インコーポレイテッド 生物活性分子の送達のための微粒子化デバイスおよびその使用方法
JP5244103B2 (ja) * 2006-08-09 2013-07-24 ホームステッド クリニカル コーポレイション 器官特異的蛋白質およびその使用方法
WO2008053478A2 (en) * 2006-10-30 2008-05-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for inhibiting hiv-1 replication and integrase activity
WO2008103265A2 (en) * 2007-02-16 2008-08-28 The Brigham And Women's Hospital, Inc. Methods of using ledgf/p75
CA2728363C (en) * 2008-06-26 2019-02-19 Orphazyme Aps Use of hsp70 as a regulator of enzymatic activity
GB0812742D0 (en) * 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
US10234453B2 (en) * 2011-07-01 2019-03-19 Inova Diagnostics, Inc. Method for increasing specificity of diagnostic tests for autoimmune diseases
US9526760B2 (en) * 2012-05-21 2016-12-27 The Regents Of The University Of Colorado, A Body Corporate LEDGF peptides and formulations thereof for treatment of degenerative disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120028889A1 (en) * 2002-09-26 2012-02-02 K.U. Leuven Research & Development Integrase cofactor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RINKU BAID等: "LEDGF1-326 Decreases P23H and Wild Type Rhodopsin Aggregates and P23H Rhodopsin Mediated Cell Damage in Human Retinal Pigment Epithelial Cells", 《PLOS ONE》, vol. 6, no. 9, 30 September 2011 (2011-09-30), pages 24616, XP055175476, DOI: 10.1371/journal.pone.0024616 *
贾梦虹等: "超临界抗溶剂法制备缓释药物微粒", 《医药工程设计》, vol. 28, no. 6, 31 December 2007 (2007-12-31) *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348544A (zh) * 2015-07-13 2018-07-31 首尔大学校产学协力团 用于抑制血管生成的含有纳米颗粒-玻璃体基蛋白质复合物作为活性成分的组合物及其用途
CN108348544B (zh) * 2015-07-13 2021-01-22 首尔大学校产学协力团 用于抑制血管生成的含有纳米颗粒-玻璃体基蛋白质复合物作为活性成分的组合物及其用途

Also Published As

Publication number Publication date
RU2617964C2 (ru) 2017-04-28
BR112014028951A8 (pt) 2021-09-14
JP2015519343A (ja) 2015-07-09
IN2014MN02461A (enExample) 2015-07-10
AU2013266468A1 (en) 2014-12-18
US9526760B2 (en) 2016-12-27
WO2013177198A1 (en) 2013-11-28
EP2852399A1 (en) 2015-04-01
ES2791251T3 (es) 2020-11-03
RU2014151603A (ru) 2016-07-10
EP2852399A4 (en) 2016-03-23
US20150147404A1 (en) 2015-05-28
DK2852399T3 (da) 2020-05-04
JP2018172386A (ja) 2018-11-08
BR112014028951A2 (pt) 2017-07-25
EP2852399B1 (en) 2020-02-19
AU2013266468B2 (en) 2017-11-09
CN110054677A (zh) 2019-07-26
US10221226B2 (en) 2019-03-05
CA2873771A1 (en) 2013-11-28
US20170129929A1 (en) 2017-05-11
JP6632376B2 (ja) 2020-01-22

Similar Documents

Publication Publication Date Title
CN107206009B (zh) 用于治疗视觉障碍的组合物和方法
EP2968471B1 (en) Peptides for use in the topical treatment of retinal neurodegenerative diseases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
US9102763B2 (en) Controlled release of ocular biopharmaceuticals using bioresponsive protein polymers
JP2018172386A (ja) 変性障害の処置のためのｌｅｄｇｆペプチドおよびその製剤
AU2021286438B2 (en) Compositions and methods for prevention and treatment of corneal haze and scarring
CA2958874A1 (en) Compositions and methods to treat and/or prevent vision disorders of the lens of the eye
EP3238746B1 (en) High-density lipoprotein, and delivery of drug to posterior segment of eye by ocular instillation of said cytophilic peptide-fused high-density lipoprotein
CN116570706A (zh) 使用多肽治疗白内障的方法
JP2014501748A (ja) 涙代用物
US9701713B2 (en) Compositions and methods for introduction of macromolecules into cells
RU2481118C2 (ru) Вакцинотерапия неоваскуляризации сосудистой оболочки глаза
Li et al. Alkaline phosphatase-responsive hydrogel for efficient management of autoimmune intraocular inflammation
US20120165268A1 (en) P53 fusion proteins and methods of making and using thereof
Baid et al. Biosynthesis, Characterization, and Efficacy in Retinal Degenerative Diseases of Lens Epithelium-derived Growth Factor Fragment (LEDGF1–326), a Novel Therapeutic Protein
Zhu et al. Noninvasive Framework Nucleic Acid Eye Drops for Retinal Administration
WO2024115767A1 (en) Nomacopan-pas fusion proteins
HK40073385B (en) Methods for treating cataracts using polypeptides
HK40073385A (en) Methods for treating cataracts using polypeptides
HK40091461A (zh) 使用多肽治疗白内障的方法
WO2021120937A1 (zh) 转甲状腺素蛋白进入眼内以及在制备滴剂中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150325